Distributor inventory
Glimepiride 2 mg + Metformin Hydrochloride 500 mg (sustained/extended release) + Voglibose 0.2 mg (per tablet)
Type 2 diabetes mellitus (in adults) when blood sugar is not adequately controlled with diet, exercise and dual therapy; helps control post-meal (postprandial) and fasting glucose.
Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin reduces glucose production in the liver and improves insulin sensitivity. Voglibose delays intestinal carbohydrate absorption, thereby reducing post-meal blood glucose spikes.
Oral tablet; take exactly as prescribed, usually once daily with/after meals (often with breakfast or main meal) to reduce stomach upset and hypoglycaemia risk. Swallow whole (do not crush/chew if SR/ER). Maintain diet and exercise; monitor blood glucose regularly.
Common side effects of GLUCONORM VG 2 may include:
Risk of hypoglycaemia (higher with missed meals, excess exercise, alcohol, or other antidiabetics); carry glucose. Metformin may rarely cause lactic acidosis—risk increases in kidney/liver impairment, dehydration, severe infection, hypoxia/heart failure; avoid if severe renal impairment and stop temporarily during acute illness. Voglibose may cause gastrointestinal discomfort; avoid in intestinal obstruction or severe digestive disorders. Monitor kidney function, liver function, and HbA1c; caution in elderly. Inform doctor before surgery or iodinated contrast scans—metformin may need temporary discontinuation.
